More news from ECTRIMS 2016: Watch presentations and interviews with leading MS experts
Please watch the interesting debate on the question “Do we still have unmet needs in MS therapy” between Gavin Giovannoni and Heinz Wiendl, comparing the ‘old’ immune-modulating therapies with the ‘new’ immunosuppressing treatments.
A new way to distinguish between MS types based on metabolic profiles is proposed by Daniel Anthony from the University of Oxford who is one of the winners of this year’s GMSI award. He talks about biomarker analysis in blood using nuclear magnetic resonance spectroscopy (NMR) as a tool to help remove uncertainty with MS staging.
In an interview taken at ECTRIMS, Prof Fredrikson from the Karolinska University Hospital Huddinge, Stockholm, speaks about the importance of differential diagnosis in MS patients, stating that even in well-established MS clinics there is a 5-10% rate of misdiagnosis.
Ellen Butler, Faith Matcham, Trudie Chalder
Multiple Sclerosis and Related Disorders, November 2016, Pages 145 - 168
Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings
Vasilios K. Kimiskidis, Vasileios Papaliagkas, Kyriaki Sotirakoglou, Zoi K. Kouvatsou, Victoria K. Kapina, Efrosini Papadaki, Vaia Tsimourtou, Elvira Masoura, Dimitrios A. Kazis, Sotirios Papayiannopoulos, Triantafyllos Geroukis, Sevasti Bostanjopoulou
Multiple Sclerosis and Related Disorders, November 2016, Pages 192 - 197
Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study
Takahiko Saida, Jun-ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, JT Tibung, Nisha Lucas, Meena Subramanyam, On behalf of Natalizumab Trial Principal Investigators.
Multiple Sclerosis and Related Disorders, January 2017, Pages 25 - 31
Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders
Felix Schmidt, Hanna Zimmermann, Janine Mikolajczak, Frederike C. Oertel, Florence Pache, Maria Weinhold, Johann Schinzel, Judith Bellmann-Strobl, Klemens Ruprecht, Friedemann Paul, Alexander U. Brandt
Multiple Sclerosis and Related Disorders, January 2017, Pages 45 - 50
The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS
Sarah A. Morrow, Heather Rosehart, Andrew M. Johnson
Multiple Sclerosis and Related Disorders, January 2017, Pages 4 - 9
About the Editors
- Timothy Vartanian, Professor at the Brain and Mind Research Institute and the Department of Neurology, Weill Cornell Medical College, Cornell...
- Claire S. Riley, MD is an assistant attending neurologist and assistant professor of neurology in the Neurological Institute, Columbia University,...
- Rebecca Farber, MD is an attending neurologist and assistant professor of neurology at the Neurological Institute, Columbia University, in New...
- Feb 201723Feb 201725Address details: Omni Orlando Resort at ChampionsGate 1500 Masters Boulevard ChampionsGate, FL 33896 (407) 390-6664The Americas Committee for Treatment and Research in Multiple Sclerosis is pleased to welcome you to the second annual stand-alone...Orlando, United States
- Mar 201718Mar 201722Little Rock, Arkansas, United StatesMeetings of the American Society for Neurochemistry (ASN) include plenary lectures, symposia, colloquia and workshops over the course of four...Little Rock, United States
- Mar 201723Mar 201726Athens, GreeceThe World Congress on Controversies in Neurology (CONy) addresses the problem that conferences frequently provide a vast amount of clinical...Athens, Greece